X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SANOFI INDIA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SANOFI INDIA GSK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 66.9 34.4 194.8% View Chart
P/BV x 11.7 6.9 170.1% View Chart
Dividend Yield % 1.1 1.3 82.5%  

Financials

 GSK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
SANOFI INDIA
Dec-16
GSK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,8384,560 84.2%   
Low Rs2,6374,400 59.9%   
Sales per share (Unadj.) Rs354.21,028.5 34.4%  
Earnings per share (Unadj.) Rs39.8129.0 30.8%  
Cash flow per share (Unadj.) Rs42.9186.0 23.1%  
Dividends per share (Unadj.) Rs30.0068.00 44.1%  
Dividend yield (eoy) %0.91.5 61.0%  
Book value per share (Unadj.) Rs236.9753.6 31.4%  
Shares outstanding (eoy) m84.7023.03 367.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.4 209.8%   
Avg P/E ratio x81.434.7 234.4%  
P/CF ratio (eoy) x75.524.1 313.5%  
Price / Book Value ratio x13.75.9 229.9%  
Dividend payout %75.452.7 143.1%   
Avg Mkt Cap Rs m274,216103,174 265.8%   
No. of employees `0004.73.6 129.6%   
Total wages/salary Rs m4,8303,592 134.5%   
Avg. sales/employee Rs Th6,387.06,537.7 97.7%   
Avg. wages/employee Rs Th1,028.3991.4 103.7%   
Avg. net profit/employee Rs Th717.1819.8 87.5%   
INCOME DATA
Net Sales Rs m30,00023,686 126.7%  
Other income Rs m728708 102.9%   
Total revenues Rs m30,72824,394 126.0%   
Gross profit Rs m4,1905,281 79.3%  
Depreciation Rs m2631,313 20.0%   
Interest Rs m015 0.0%   
Profit before tax Rs m4,6554,661 99.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7441,691 103.1%   
Profit after tax Rs m3,3682,970 113.4%  
Gross profit margin %14.022.3 62.6%  
Effective tax rate %37.536.3 103.3%   
Net profit margin %11.212.5 89.5%  
BALANCE SHEET DATA
Current assets Rs m16,74215,673 106.8%   
Current liabilities Rs m7,2026,678 107.9%   
Net working cap to sales %31.838.0 83.7%  
Current ratio x2.32.3 99.0%  
Inventory Days Days5276 68.2%  
Debtors Days Days2122 93.1%  
Net fixed assets Rs m8,6358,098 106.6%   
Share capital Rs m847230 367.8%   
"Free" reserves Rs m19,22217,088 112.5%   
Net worth Rs m20,06917,356 115.6%   
Long term debt Rs m100-   
Total assets Rs m30,03825,400 118.3%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.9 107.1%   
Return on assets %11.211.8 95.4%  
Return on equity %16.817.1 98.1%  
Return on capital %25.526.9 94.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m5287,145 7.4%   
Fx outflow Rs m7,1936,846 105.1%   
Net fx Rs m-6,665299 -2,229.1%   
CASH FLOW
From Operations Rs m2,3603,226 73.2%  
From Investments Rs m3,008-1,555 -193.4%  
From Financial Activity Rs m-5,108-1,818 280.9%  
Net Cashflow Rs m260-147 -177.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 60.4 83.9%  
Indian inst/Mut Fund % 10.2 14.4 70.8%  
FIIs % 23.8 14.6 163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 15,184 672.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PFIZER  TORRENT PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ASTRAZENECA PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Analysis of IPOs Launched in 2018, Governments Effort to Boost Aviation Infrastructure and Key Stocks in Action Today(Pre-Open)

The returns from initial public offers (IPOs) launched in 2018 are mixed. Comparing the gain/ (loss) since the listing date as mentioned in the last column, seven stocks are in the negative territory.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS